384 related articles for article (PubMed ID: 25712626)
21. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
[TBL] [Abstract][Full Text] [Related]
22. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
25. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
[TBL] [Abstract][Full Text] [Related]
26. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
Ramanathan S; Jin F; Sharma S; Kearney BP
Clin Pharmacokinet; 2016 Jan; 55(1):33-45. PubMed ID: 26242379
[TBL] [Abstract][Full Text] [Related]
27. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
29. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Ma S; Chan RJ; Gu L; Xing G; Rajakumaraswamy N; Ruzicka BB; Wagner-Johnston ND
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e432-e448. PubMed ID: 33516721
[TBL] [Abstract][Full Text] [Related]
30. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
31. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
[TBL] [Abstract][Full Text] [Related]
32. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
O'Brien SM; Lamanna N; Kipps TJ; Flinn I; Zelenetz AD; Burger JA; Keating M; Mitra S; Holes L; Yu AS; Johnson DM; Miller LL; Kim Y; Dansey RD; Dubowy RL; Coutre SE
Blood; 2015 Dec; 126(25):2686-94. PubMed ID: 26472751
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.
Gopal AK; Fanale MA; Moskowitz CH; Shustov AR; Mitra S; Ye W; Younes A; Moskowitz AJ
Ann Oncol; 2017 May; 28(5):1057-1063. PubMed ID: 28327905
[TBL] [Abstract][Full Text] [Related]
34. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
[TBL] [Abstract][Full Text] [Related]
35. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
[TBL] [Abstract][Full Text] [Related]
36. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman RR; Sharman JP; Coutre SE; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn I; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Stilgenbauer S; Cramer P; Aiello M; Johnson DM; Miller LL; Li D; Jahn TM; Dansey RD; Hallek M; O'Brien SM
N Engl J Med; 2014 Mar; 370(11):997-1007. PubMed ID: 24450857
[TBL] [Abstract][Full Text] [Related]
37. Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):8-9. PubMed ID: 24870874
[No Abstract] [Full Text] [Related]
38. Idelalisib: targeting PI3Kδ in B-cell malignancies.
Gilbert JA
Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
[No Abstract] [Full Text] [Related]
39. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
40. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Sujobert P; Rioufol C; Salles GA
Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
